Brand Navigation Banner

Treat with foresight
namd

nAMD

Unsurpassed and sustained vision gains with proactive extended dosing1,2

2X

Long-lasting VEGF-A suppression

Up to 2x  longer than ranibizumab3-5

proactive Extended dosing

Proactive extended dosing

By Week 96 in the ALTAIR study:

  • Up to 60% of patients reached an injection interval of ≥12 weeks1,2
  • Up to 46% of patients reached an injection interval of 16 weeks2
Decreased injection frequency

Decreased injection frequency

Achieve sustained VA gains with as few as 3 injections in Year 2 1

EYLEA®: YOUR CHOICE FOR FOR PROACTIVE TREAT AND EXTEND UP TO Q161

Sustained VEGF supression with EYLEA®1

Mean Duration

Mean duration of VEGF-A suppression with EYLEA®:67+/-14 days

Mean duration of VEGF-A suppression with ranibizumab 34+/-5days

 Definite VEGF suppression

 Uncertain suppression status

Uncertain end of suppression

 

Long-lasting anti-VEGF activity upto 2x longer than a ranibizumab (P<0.0001)4,5

VA GAINS MAINTAINED AT YEAR 2 WITH PROACTIVE EXTENDED DOSING2

Q12 and beyond: VA gains observed in Year 1 and Year 2 of ALTAIR1,2

    2-WEEK EXTENSION (n=124 EYES)
    Mean Change in BCVA
    4-WEEK EXTENSION (n=123 EYES)
    Mean Change in BCVA

    Mean number of injections at 96 weeks for both groups: 10.4 injections2

    ACHIEVE UNSURPASSED AND SUSTAINED VA GAINS WITH EYLEA®

    Treat and extend patients up to Q161,2,6

      4-WEEK EXTENSION
      Proportion of patients
      Proportion of patients
      • Proportion of patients achieving ≥12-week dosing at 96 weeks
      • Proportion of patients achieving 16-week dosing at 96 weeks
      2-WEEK EXTENSION
      Proportion of patients
      Proportion of patients
      • Proportion of patients achieving ≥12-week dosing at 96 weeks
      • Proportion of patients achieving 16-week dosing at 96 weeks

      Achieve sustained VA gains with as few as 3 injections in Year 2 when proactive T&E is used with EYLEA®1,2

      DOSING

      DOSING

      DOSING

      Pro-active dosing options across indications1

      Read more
      Dosing

      MOA

      MOA

      MOA

      Unique multi-targeted trap mechanism7

      Read more
      MOA
      Pre-Filled Syringe Pre-Filled Syringe

      INTRODUCING THE NEW EYLEA® PRE-FILLED SYRINGE

      WHAT'S INSIDE MAKES THE DIFFERENCE

       

      Syringe cap with a simple twist mechanism, for controlled opening1

      LEARN MORE

      References:

      • EYLEA® (aflibercept solution for injection) Summary of Product Characteristics. Berlin, Germany: Bayer Pharma AG. Return to content
      • Ohji M, Takahashi K, Okada AA, Kobayashi M, Matsuda Y, Terano Y; for ALTAIR Investigators. Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative age-related macular degeneration: 52- and 96-week findings from ALTAIR: a randomized controlled trial [published online ahead of print February 3, 2020]. Adv Ther. doi: 10.1007/s12325-020-01236-x. Return to content
      • Muether PS, Hermann MM, Dröge K, Kirchhof B, Fauser S. Long-term stability of vascular endothelial growth factor suppression time under ranibizumab treatment in age-related macular degeneration. Am J Ophthalmol. 2013;156:989-993. Return to content
      • Fauser S, Muether PS. Clinical correlation to differences in ranibizumab and aflibercept vascular endothelial growth factor suppression times. Br J Ophthalmol. 2016;100:1494-1498. Return to content
      • Fauser S, Schwabecker V, Muether PS. Suppression of intraocular vascular endothelial growth factor during aflibercept treatment of age-related macular degeneration. Am J Ophthalmol. 2014;158:532-536. Return to content
      • Richard G, Monés J, Wolf S, et al. Scheduled versus pro re nata dosing in the VIEW trials. Ophthalmology. 2015;122:2497-2503. Return to content
      • Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap,ranibizumab and bevacizumab. Angiogenesis. 2012;15;171-185. Return to content